Media Releases
Corporate News
May 22, 2013
Roche presents new, fully automated lab solution at Europe's largest diagnostics conference
Roche announced today at the IFCC Euromedlab in Milan, Italy that it will soon introduce the cobas 8100 automated workflow ...
more
May 16, 2013
Roche's obinutuzumab (GA101) significantly reduced the risk of disease progression or death in people with one of the most common forms of blood cancer
Roche today announced the first results from CLL11, a phase III study of the investigational medicine GA101 which is being ...
more
May 15, 2013
FDA approves Tarceva (erlotinib) tablets and cobas EGFR Mutation Test for specific type of lung cancer
Tarceva is the first personalised medicine approved for the initial treatment of people with EGFR mutation-positive advanced ...
more
May 15, 2013
Roche to present important new data reflecting broad cancer pipeline at ASCO
First phase III data on obinutuzumab (GA101) in one of the most commonly diagnosed blood cancers;
Early stage data on investigational ...
more
April 30, 2013
FDA approves ACTEMRA for children living with a rare form of arthritis
Roche announced today that the U.S. Food and Drug Administration (FDA) has approved ACTEMRA (tocilizumab) for the treatment ...
more
April 26, 2013
CHMP recommends conditional EU approval of Roche's Erivedge for advanced basal cell carcinoma, a rare but potentially devastating form of skin cancer
Roche announced today that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has recommended ...
more
April 23, 2013
Roche to change Applied Science business structure
Roche today announced changes to the management and set-up of its life-science business. The Applied Science Business Area ...
more
April 15, 2013
Roche and Ascletis enter collaboration to advance treatment options for Chinese patients with Hepatitis C
Roche and Ascletis announced today that they have entered into a collaboration to develop and commercialize Roche’s ...
more
April 11, 2013
Roche Group posts strong sales growth in the first quarter
Group sales increase 6% at CER to 11.6 billion Swiss francs; Pharmaceuticals sales rise 7% to 9.2 billion Swiss francs, driven ...
more
April 04, 2013
Roche launches new test for diagnosis and monitoring of thyroid cancer
Roche today announced the global launch (except US) of Elecsys Calcitonin, a new laboratory test for the diagnosis and lifelong ...
more
March 18, 2013
Roche's Pegasys receives EU approval for the treatment of chronic hepatitis C in children five years of age and older
Roche announced today that the European Medicines Agency (EMA) has expanded the approval of Pegasys (peginterferon alfa-2a) ...
more
March 06, 2013
FDA approves new Roche test to evaluate response to hepatitis C therapy
Viral load test uses a novel dual-probe approach designed to manage patients being treated with antiviral therapies.
more
March 05, 2013
Roche Chairman Franz B. Humer announces that he will not stand for re-election in 2014
Franz B. Humer, Chairman of the Board of Directors of the Roche Group, announced at today’s Annual General Meeting that ...
more
March 05, 2013
Roche obtains EU approval for PERJETA, a new personalised treatment for aggressive type of breast cancer
Roche today announced that the European Medicines Agency (EMA) has approved PERJETA(pertuzumab) for patients with previously ...
more
February 26, 2013
Roche launches new process for accessing clinical trial data
Roche today announced that it is expanding access to its clinical trial data for third party researchers. Roche will work ...
more
February 22, 2013
FDA approves Roche's Kadcyla (trastuzumab emtansine), the first antibody-drug conjugate for treating HER2-positive metastatic breast cancer
New personalised medicine helped people in Phase III study live longer, compared to standard treatment
more
January 31, 2013
Obinutuzumab (GA101) significantly improved progression-free survival in people with chronic lymphocytic leukemia (CLL)
Roche today announced positive results from stage 1 of CLL11, a phase III randomised study to investigate the efficacy and ...
more
January 30, 2013
Roche delivers strong 2012 results
Group sales rise 4% to 45.5 billion Swiss francs due to oncology sales, clinical laboratory business; Core EPS 10% higher ...
more
January 24, 2013
FDA approves new use of Avastin plus chemotherapy for people with metastatic colorectal cancer
Roche today announced that the US Food and Drug Administration (FDA) has approved a new use of Avastin (bevacizumab) in combination ...
more
January 15, 2013
Change to the Roche Corporate Executive Committee
Roche today announced that John C. Reed, M.D., Ph.D., has been appointed Head of Roche Pharma Research and Early Development ...
more